These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 19491681)

  • 21. Controversies in contraception.
    Pitts SA; Emans SJ
    Curr Opin Pediatr; 2008 Aug; 20(4):383-9. PubMed ID: 18622191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone mineral density in young women aged 19-24 after 4-5 years of exclusive and mixed use of hormonal contraception.
    Beksinska ME; Kleinschmidt I; Smit JA; Farley TM; Rees HV
    Contraception; 2009 Aug; 80(2):128-32. PubMed ID: 19631787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device.
    van Hylckama Vlieg A; Helmerhorst FM; Rosendaal FR
    Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2297-300. PubMed ID: 20798377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate.
    Sanches L; Marchi NM; Castro S; Juliato CT; Villarroel M; Bahamondes L
    Contraception; 2008 Nov; 78(5):365-9. PubMed ID: 18929732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women.
    Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
    Contraception; 2004 Feb; 69(2):99-104. PubMed ID: 14759613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contraception continuation rates and reasons for discontinuation in Zahedan, Islamic Republic of Iran.
    Rakhshani F; Mohammadi M
    East Mediterr Health J; 2004 May; 10(3):260-7. PubMed ID: 16212200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
    Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
    Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contraceptive considerations in overweight teens.
    Kaneshiro B; Edelman A
    Curr Opin Obstet Gynecol; 2011 Oct; 23(5):344-9. PubMed ID: 21666461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health.
    Petitti DB; Piaggio G; Mehta S; Cravioto MC; Meirik O
    Obstet Gynecol; 2000 May; 95(5):736-44. PubMed ID: 10775740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.
    Cromer BA; Scholes D; Berenson A; Cundy T; Clark MK; Kaunitz AM;
    J Adolesc Health; 2006 Aug; 39(2):296-301. PubMed ID: 16857545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlled trial with a monthly combination injectable contraceptive in Europe.
    Brucker C
    Gynecol Endocrinol; 2001 Aug; 15 Suppl 3():11-4. PubMed ID: 11570312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormonal contraception and bone metabolism: a systematic review.
    Nappi C; Bifulco G; Tommaselli GA; Gargano V; Di Carlo C
    Contraception; 2012 Dec; 86(6):606-21. PubMed ID: 22717184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women.
    Lizarelli PM; Martins WP; Vieira CS; Soares GM; Franceschini SA; Ferriani RA; Patta MC
    Contraception; 2009 Jan; 79(1):35-40. PubMed ID: 19041439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depot-medroxyprogesterone acetate: an update.
    Bakry S; Merhi ZO; Scalise TJ; Mahmoud MS; Fadiel A; Naftolin F
    Arch Gynecol Obstet; 2008 Jul; 278(1):1-12. PubMed ID: 18470526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of combined and progestogen-only contraceptives on bone mineral density.
    Sarfati J; de Vernejoul MC
    Joint Bone Spine; 2009 Mar; 76(2):134-8. PubMed ID: 19181558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormonal contraception and blood lead levels in inner-city adolescent girls.
    Iglesias EA; Coupey SM; Markowitz ME
    J Pediatr Adolesc Gynecol; 2008 Oct; 21(5):269-73. PubMed ID: 18794022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No bones about it--depot medroxyprogesterone acetate remains an excellent contraceptive option for adolescents.
    Rager KM
    J Pediatr Adolesc Gynecol; 2005 Jun; 18(3):187-8. PubMed ID: 15970254
    [No Abstract]   [Full Text] [Related]  

  • 38. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate.
    Perrotti M; Bahamondes L; Petta C; Castro S
    Fertil Steril; 2001 Sep; 76(3):469-73. PubMed ID: 11532466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female.
    Bonny AE; Harkness LS; Cromer BA
    Adolesc Med Clin; 2005 Oct; 16(3):569-84. PubMed ID: 16183540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended cycling or continuous use of hormonal contraceptives for female adolescents.
    Gold MA; Duffy K
    Curr Opin Obstet Gynecol; 2009 Oct; 21(5):407-11. PubMed ID: 19528798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.